Last reviewed · How we verify
Peri-urethral and clitoral injections — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Peri-urethral and clitoral injections (Peri-urethral and clitoral injections) — Center for Vulvovaginal Disorders.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Peri-urethral and clitoral injections TARGET | Peri-urethral and clitoral injections | Center for Vulvovaginal Disorders | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Peri-urethral and clitoral injections CI watch — RSS
- Peri-urethral and clitoral injections CI watch — Atom
- Peri-urethral and clitoral injections CI watch — JSON
- Peri-urethral and clitoral injections alone — RSS
Cite this brief
Drug Landscape (2026). Peri-urethral and clitoral injections — Competitive Intelligence Brief. https://druglandscape.com/ci/peri-urethral-and-clitoral-injections. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab